# Avista Pharma Solutions, Inc. dba Cambrex - Inspection Records

Source: https://www.keypedia.com/companies/avista-pharma-solutions-inc-dba-cambrex/abe58c04-c144-4601-a4df-a290928bafa5

> Inspection records and compliance data for Avista Pharma Solutions, Inc. dba Cambrex in Agawam, Massachusetts. Access full analysis and detailed observations.

---

## Details

- Name: Avista Pharma Solutions, Inc. dba Cambrex
- FEI Number: 1220785
- City: Agawam
- State: Massachusetts
- Country Name: United States
- Address Line 1: 104 Gold St
- Zip Code: 01001
- Business Operations: API/FDF ANALYTICAL TESTING

## Related Documents

- [EIR - Avista Pharma Solutions, Inc. dba Cambrex - 2025-07-25](https://www.keypedia.com/records/eir/avista-pharma-solutions-inc-dba-cambrex/a94e807f-a60a-40fd-b66f-102c3a957832) — source: FDA, date: July 25, 2025
- [483 - Avista Pharma Solutions, Inc. dba Cambrex - 2025-07-25](https://www.keypedia.com/records/483/avista-pharma-solutions-inc-dba-cambrex/dda545e9-7e67-4c8e-a7de-c638725bd84e) — source: FDA, date: July 25, 2025
- [483 - Avista Pharma Solutions, Inc. dba Cambrex - 2025-07-25](https://www.keypedia.com/records/483/avista-pharma-solutions-inc-dba-cambrex/887e62a3-6beb-4a60-b52c-33a782b5d2ca) — source: FDA, date: July 25, 2025
- [483 - Avista Pharma Solutions, Inc. dba Cambrex - 2025-07-25](https://www.keypedia.com/records/483/avista-pharma-solutions-inc-dba-cambrex/9114de19-b62a-4740-b343-34d5774c7c21) — source: FDA, date: July 25, 2025
- [FDA Inspection 1278383 - Avista Pharma Solutions, Inc. dba Cambrex - 2025-07-25](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/07d264c9-9218-4fc2-92ce-25f1f2348432) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 25, 2025
- [EIR - Avista Pharma Solutions, Inc. dba Cambrex - 2019-12-18](https://www.keypedia.com/records/eir/avista-pharma-solutions-inc-dba-cambrex/d31551c3-16ba-4f4a-aaac-b85e5bf22bcc) — source: FDA, date: December 18, 2019
- [FDA Inspection 1113974 - Avista Pharma Solutions, Inc. dba Cambrex - 2019-12-18](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/43a50e53-b23a-4132-b1c6-e57509860e23) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 18, 2019
- [FDA Inspection 1067530 - Avista Pharma Solutions, Inc. dba Cambrex - 2018-09-05](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/d175dd6d-7561-482d-b246-920920a41ec5) — classification: No Action Indicated (NAI), source: FDA, date: September 5, 2018
- [FDA Inspection 988732 - Avista Pharma Solutions, Inc. dba Cambrex - 2016-06-15](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/c88cfac6-d9aa-4a5a-adc0-be20464a8181) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 15, 2016
- [483 - Avista Pharma Solutions, Inc. dba Cambrex - 2013-09-27](https://www.keypedia.com/records/483/avista-pharma-solutions-inc-dba-cambrex/9f9dbbb7-e4b8-44a3-81c1-7d55709ef9c2) — source: FDA, date: September 27, 2013
- [FDA Inspection 850250 - Avista Pharma Solutions, Inc. dba Cambrex - 2013-09-27](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/51fdbe29-4c8a-4db0-b664-5ef7edf67340) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 27, 2013
- [FDA Inspection 696758 - Avista Pharma Solutions, Inc. dba Cambrex - 2010-10-27](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/d67de3ad-526d-40d3-99fd-0b58abf42d77) — classification: No Action Indicated (NAI), source: FDA, date: October 27, 2010

## Related Companies

- [Labcorp Early Development Laboratories, Inc.](https://www.keypedia.com/companies/labcorp-early-development-laboratories-inc/e6487660-cd04-47c4-879b-cc0248eba943)
- [Jiangsu Hengrui Pharmaceuticals Co., Ltd.](https://www.keypedia.com/companies/jiangsu-hengrui-pharmaceuticals-co-ltd/d8430568-25ba-4cb0-a549-75fa7caf0a45)
- [Gateway Analytical, LLC.](https://www.keypedia.com/companies/gateway-analytical-llc/9ef2f86f-03e6-464f-85c4-35a2ef6d82b9)
- [PPD Development, L.P.](https://www.keypedia.com/companies/ppd-development-lp/c8b3d3b0-5856-4714-bc30-21345649d782)
- [Accelerated Analytical Laboratories Inc.](https://www.keypedia.com/companies/accelerated-analytical-laboratories-inc/e32c5f35-c700-4a7d-a217-97e5105ae3a5)
- [Lexamed, Ltd](https://www.keypedia.com/companies/lexamed-ltd/b54f148c-75ae-4ec5-aee3-d675b90f3f88)
- [CHARLES RIVER LABORATORIES](https://www.keypedia.com/companies/charles-river-laboratories/079ae978-a3c8-4c11-a1dc-3f036f3f6df0)
- [Southern Spectrographic Laboratory, Inc.](https://www.keypedia.com/companies/southern-spectrographic-laboratory-inc/3c5fe8da-6d1c-4206-b620-e4e4f2d3f5f2)
- [CHRI Laboratories, Inc.](https://www.keypedia.com/companies/chri-laboratories-inc/a16b4ec4-b9e0-424b-84b0-74cef5de1ed7)
- [Prompt Praxis Laboratories LLC](https://www.keypedia.com/companies/prompt-praxis-laboratories-llc/f8ac91d0-1aec-4588-bfeb-ed7e871aaf04)

## Related Officers

- [Assuring that quality medicines are available to the American public](https://www.keypedia.com/people/maya-m-davis/4180239e-5b21-4f9c-9ff0-6bbe5222f740)
- [Regional Manager](https://www.keypedia.com/people/jonah-s-ufferfilge/6bcd2028-9aca-4704-bd7b-c835874fad9d)
- [Arizona Market President](https://www.keypedia.com/people/john-p-mistler/7b2d423d-46cc-48bd-aa5a-4ae794888060)
- [M.S., Consumer Safety Officer at FDA](https://www.keypedia.com/people/daniel-l-zheng/5e3d993f-654e-4d40-a2c8-69c5e396499f)
- [investigator](https://www.keypedia.com/people/ifechimere-i-okafor/c48399bf-47d9-4562-9130-1e6731eca07d)